静脉氨磺必利10mg治疗术后恶心呕吐对QTc间期无显著延长
本研究为随机双盲安慰剂对照三周期交叉试验,纳入30名健康志愿者,评估静脉氨磺必利10mg单用或与昂丹司琼4mg联用对QTcF的影响。结果显示最大ΔΔQTcF分别为8.0ms和7.3ms,未超过临床关注阈值,且无QTc异常值,表明该剂量对QT间期无临床显著影响。
要点
- 静脉氨磺必利10mg单用或联用昂丹司琼4mg均未导致临床显著的QTcF延长。
- 两药联用时最大ΔΔQTcF为7.3ms(90%CI 5.48-9.16),未超过10ms关注阈值。
- 研究中未出现绝对QTcF>480ms或较基线增加>30ms的异常值。
核心结论
- 静脉氨磺必利10mg单用或与昂丹司琼4mg联用对QT间期无临床显著影响。
研究设计与样本
- 随机、双盲、安慰剂对照、三周期交叉研究,纳入30名18-65岁健康志愿者,29名完成全部周期。
主要发现
- 首次和第二次氨磺必利10mg后最大ΔΔQTcF分别为5.2ms(90%CI 3.53-6.96)和8.0ms(90%CI 5.49-10.58)。
- 氨磺必利与昂丹司琼联用后最大ΔΔQTcF为7.3ms(90%CI 5.48-9.16)。
- 氨磺必利浓度-ΔQTcF关系斜率为0.006 ms/ng/mL(90%CI 0.0020-0.0098)。
- 任何周期均未出现绝对QTcF>480ms或较基线增加>30ms的异常值。
临床怎么用
- 对于术后恶心呕吐患者,静脉氨磺必利10mg可单独或与昂丹司琼4mg联用,无需过度担忧QT间期延长。
局限性
- 研究对象为健康志愿者,非术后患者,临床外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) are significant issues in surgical patients, and additional treatment options are needed. Dopaminergic antiemetics have been popular for their efficacy, but their use has been limited by safety concerns, especially the potential for torsade de pointes arising from QT interval prolongation. Intravenous (IV) amisulpride, a dopamine D2 and D3 antagonist shown to be effective at preventing and treating PONV at doses of 5 and 10 mg, respectively, has a dose-dependent effect on QT but at 5 mg is not associated with clinically meaningful prolongation of the heart rate-corrected QT (QTc) interval. This study was designed to evaluate the QT effect of a 10-mg dose of amisulpride, alone and when simultaneously coadministered with ondansetron, an antiemetic of a different class, also known to prolong the QT interval. METHODS: In this randomized, double-blind, placebo-controlled, 3-period, crossover study, healthy male and female volunteers 18-65 years of age received IV, in a random sequence: (1) amisulpride 10 mg given twice, 2 hours apart; (2) amisulpride 10 mg and ondansetron 4 mg, given simultaneously; and (3) placebo. RESULTS: Thirty subjects were enrolled, and 29 completed all 3 treatment periods. The largest mean placebo-corrected change-from-baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) (ΔΔQTcF) after the first and second amisulpride dose was 5.2 milliseconds (90% confidence interval [CI], 3.53-6.96 milliseconds) and 8.0 milliseconds (90% CI, 5.49-10.58 milliseconds), respectively. After coadministration of amisulpride and ondansetron, the largest mean ΔΔQTcF was 7.3 milliseconds (90% CI, 5.48-9.16 milliseconds). The slope of the amisulpride concentration-change-from-baseline QTcF (ΔQTcF) relationship was 0.006 ms/ng/mL (90% CI, 0.0020-0.0098). No QTc outliers (absolute QTcF value >480 milliseconds or increase from baseline >30 milliseconds) were seen in any period. CONCLUSIONS: A 10-mg dose of IV amisulpride, given alone or in combination with ondansetron, does not have a clinically significant effect on the QT interval.
引用
- Fox GM, Albayaty M, Walker JL, et al. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2021. PMID: 31913911. doi:10.1213/ANE.0000000000004538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。